Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
GlioblastomaIDH Wild-type and STAT3-positive Glioblastoma
Interventions
DIETARY_SUPPLEMENT

Silibinin as STAT3 inhibitor

Sillbrain will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Each 3.7 g sachet of Sillbrain contains 500 mg silibinin. Every patient will assume 2 sachets/day for a total of 1 g/day of silibinin.

OTHER

Placebo

Placebo will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Every patient will assume 2 sachets/day for a total of 1 g/day of placebo.

Trial Locations (16)

20089

Humanitas Cancer Center, Milan

20157

IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan

23900

Ospedale A. Manzoni Lecco, Lecco

27100

Istituto Neurologico Nazionale a Carattere Scientifico IRCCS - Fondazione Mondino, Pavia

35128

Istituto Oncologico Veneto, Padua

40139

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna

47014

IRST Dino Amadori, Meldola

50134

Azienda Ospedaliera Universitaria - Careggi, Florence

57124

USL Nord Ovest Toscana - Livorno, Livorno

80147

Ospedale del Mare, ASL Napoli1 Centro, Napoli

95123

"Azienda Ospedaliero Universitaria Policlinico G. Rodolico - San Marco ", Catania

98124

Azienda Ospedaliera Universitaria G.Martino, Messina

09047

ARNAS G.Brotzu P.O Armando Businco, Cagliari

00128

Istituto Tumori Regina Elena IRCCS, Roma

Unknown

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Policlinico San Martino - Genova, Genova

All Listed Sponsors
lead

Istituto Oncologico Veneto IRCCS

OTHER

NCT06964815 - Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients | Biotech Hunter | Biotech Hunter